Association of a Single Nucleotide Variant in TERT with Airway Disease in Japanese Rheumatoid Arthritis Patients
- PMID: 38003027
- PMCID: PMC10671651
- DOI: 10.3390/genes14112084
Association of a Single Nucleotide Variant in TERT with Airway Disease in Japanese Rheumatoid Arthritis Patients
Abstract
Interstitial lung disease and airway disease (AD) are often complicated with rheumatoid arthritis (RA) and have a poor prognosis. Several studies reported genetic associations with interstitial lung disease in RA. However, few genetic studies have examined the susceptibility to AD in RA patients. Here, we investigated whether single nucleotide variants susceptible to idiopathic pulmonary fibrosis might be associated with interstitial lung disease or AD in Japanese RA patients. Genotyping of rs2736100 [C/A] in TERT and rs1278769 [G/A] in ATP11A was conducted in 98 RA patients with usual interstitial pneumonia, 120 with nonspecific interstitial pneumonia (NSIP), 227 with AD, and 422 without chronic lung disease using TaqMan assays. An association with AD in RA was found for rs2736100 (p = 0.0043, Pc = 0.0129, odds ratio [OR] 1.40, 95% confidence interval [CI] 1.11-1.77). ATP11A rs1278769 was significantly associated with NSIP in older RA patients (>65 years, p = 0.0010, OR 2.15, 95% CI 1.35-3.40). This study first reported an association of rs2736100 with AD in RA patients and ATP11A rs1278769 with NSIP in older RA patients.
Keywords: airway disease; genetic association; nonspecific interstitial pneumonia; rheumatoid arthritis; single nucleotide variant.
Conflict of interest statement
Shigeto Tohma received honoraria from AbbVie GK., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co. Asahi Kasei Pharma Corp., Astellas Pharma Inc., and Pfizer Japan Inc. Hiroshi Furukawa received honoraria from Ayumi Pharmaceutical Corp., Pfizer Japan Inc., Luminex Japan Corp. Ltd., Ajinomoto Co. Inc. Dainippon Sumitomo Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., and Takeda Pharmaceutical Co. Shigeto Tohma was supported by research grants from Abbott Japan Co., Ltd., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corp., Merck Sharp and Dohme Inc., Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Teijin Pharma Ltd., and Astellas Pharma Inc. Hiroshi Furukawa was supported by research grants from Japan Research Foundation for Clinical Pharmacology supported by Daiichi Sankyo, Daiwa Securities Health Foundation established by Daiwa Securities Group Inc., Takeda Science Foundation run by Takeda Pharmaceutical Co., Mitsui Sumitomo Insurance Welfare Foundation established by Mitsui Sumitomo Insurance Co., Ltd., Bristol-Myers-Squibb Co., and the Nakatomi Foundation established by Hisamitsu Pharmaceutical Co. Inc. The other authors have no conflict of interest.
Similar articles
-
Association of a FAM13A variant with interstitial lung disease in Japanese rheumatoid arthritis.RMD Open. 2023 Jan;9(1):e002828. doi: 10.1136/rmdopen-2022-002828. RMD Open. 2023. PMID: 36717188 Free PMC article.
-
MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.N Engl J Med. 2018 Dec 6;379(23):2209-2219. doi: 10.1056/NEJMoa1801562. Epub 2018 Oct 20. N Engl J Med. 2018. PMID: 30345907 Free PMC article.
-
Association of human leukocyte antigen alleles with chronic lung diseases in rheumatoid arthritis.Rheumatology (Oxford). 2016 Jul;55(7):1301-7. doi: 10.1093/rheumatology/kew025. Epub 2016 Apr 5. Rheumatology (Oxford). 2016. PMID: 27048628
-
Recent advances in rheumatoid arthritis-associated interstitial lung disease.Curr Opin Pulm Med. 2020 Sep;26(5):477-486. doi: 10.1097/MCP.0000000000000710. Curr Opin Pulm Med. 2020. PMID: 32701675 Review.
-
[Interstitial lung disease in rheumatoid arthritis].Rev Med Suisse. 2011 Nov 23;7(318):2272-7. Rev Med Suisse. 2011. PMID: 22400361 Review. French.
References
-
- Stainer A., Tonutti A., De Santis M., Amati F., Ceribelli A., Bongiovanni G., Torrisi C., Iacopino A., Mangiameli G., Aliberti S., et al. Unmet needs and perspectives in rheumatoid arthritis-associated interstitial lung disease: A critical review. Front. Med. 2023;10:1129939. doi: 10.3389/fmed.2023.1129939. - DOI - PMC - PubMed
-
- Furukawa H., Oka S., Shimada K., Sugii S., Ohashi J., Matsui T., Ikenaka T., Nakayama H., Hashimoto A., Takaoka H., et al. Association of human leukocyte antigen with interstitial lung disease in rheumatoid arthritis: A protective role for shared epitope. PLoS ONE. 2012;7:e33133. doi: 10.1371/journal.pone.0033133. - DOI - PMC - PubMed
-
- Koduri G., Norton S., Young A., Cox N., Davies P., Devlin J., Dixey J., Gough A., Prouse P., Winfield J., et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: Results from an inception cohort. Rheumatology. 2010;49:1483–1489. doi: 10.1093/rheumatology/keq035. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- Teijin Pharma Limited
- Takeda Pharmaceutical Company Limited
- Pfizer Japan Inc.
- Merck Sharp and Dohme Inc.
- Mitsubishi Tanabe Pharma Corporation
- Eisai Co. Ltd.
- Chugai Pharmaceutical Co., Ltd.
- Astellas Pharma Inc.
- Abbott Japan Co. Ltd
- Bristol-Myers K.K.
- Bristol-Myers Squibb Co.
- Mitsui Sumitomo Insurance Welfare Foundation
- Takeda Science Foundation
- The Nakatomi Foundation
- Daiwa Securities Health Foundation
- Japan Research Foundation for Clinical Pharmacology
- National Hospital Organization
- Japan Agency for Medical Research and Development
- the Ministry of Health, Labour, and Welfare of Japan
- 26293123, 22591090, 15K09543, 18K08402/the Japan Society for the Promotion of Science
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases